MedDocIQ — Full-Lifecycle Physician-Led Clinical Trial Documentation for Uzbekistan and Central Asia
Physician-Led | US-Based | Uzbekistan-first | Central Asia expansion
MedDocIQ is a clinical-trial documentation partner — not a CRO. We localize and clinically validate patient-facing and regulatory documents and review protocols for documentation- and ICF-relevant execution risks. We do not perform site selection, site qualification, investigator/PI assessment, patient recruitment, monitoring, or trial management. Those remain the CRO's role — we work alongside them.
MedDocIQ provides full trial lifecycle clinical document support for clinical trials in Uzbekistan and Central Asia. From Protocol Feasibility document localization through initial ICF Cultural Localization, amendments, safety updates, and close-out documentation — we stay with your trial as your dedicated documentation partner, not a one-off vendor.
Built by a team with direct clinical trial operations experience and native Central Asian linguistic expertise. Our physician-led workflow combines clinical review with native Russian and Uzbek linguists to deliver audit-friendly documentation with tracked changes, Study Glossary, Clinical Intent Verification Note (CIVN), and Localization Validation Certificate.
Our Services
Tier 1: Trial Startup Bundle — Feasibility Document Localization to ICF Cultural Localization
The complete physician-led startup package: feasibility document localization + ICF localization in one coordinated workflow. Includes Protocol Feasibility and Readiness Memo (documentation and ICF-relevant execution risks), SoA to ICF Alignment Map, Study Glossary + Term Decision Register, tracked-changes + clean copy (RU and/or UZ), and Clinical Intent Verification Note (CIVN). Does not include site selection, investigator assessment, patient recruitment, or trial management. Pricing: Custom.
Tier 2: Protocol Feasibility Review (Uzbekistan lens — documentation focus)
Physician-led review of your English draft protocol for documentation- and ICF-relevant execution risks, ethics committee friction points, and patient-facing clarity gaps — before a single word is localized. Includes risk memo, ICF-relevant risk flags, SoA to ICF Alignment Notes, Study Glossary starter, and optional sponsor handoff call. Does not include site selection, investigator assessment, or enrollment forecasting. Pricing: Custom.
Tier 3: ICF Cultural Localization + Clinical Validation (RU/UZ) — $1,200
Native Uzbek and Russian linguists localize your ICF for patient-facing clarity, followed by physician clinical review to confirm intent and terminology consistency. Turnaround: 7 to 10 business days. Includes tracked-changes + clean copy, physician Clinical QC (GCP-aware), glossary alignment, and CIVN.
Tier 4: Second-Pass Clinical Validation (Existing RU/UZ)
Already have a RU/UZ ICF from another vendor? Our physician team reviews clinical intent, terminology consistency, and patient-facing clarity, returning a tracked correction set prepared to support ethics re-submission. Pricing: Custom.
Full Trial Lifecycle Document Support
MedDocIQ is not a one-off startup vendor. We provide ongoing documentation support throughout the entire trial lifecycle — ICF amendments, protocol amendment-driven ICF updates, safety-related consent revisions, regulatory correspondence, and close-out documentation. Because we maintain your Study Glossary and terminology decisions from day one, every subsequent document version maintains consistent clinical language and physician-validated accuracy.
Why MedDocIQ?
-
Full Trial Lifecycle Partner:
From feasibility through close-out — not just startup. We stay with your trial for every amendment, safety update, and regulatory submission.
-
Physician-Led Medical Accuracy Review:
Medical meaning reviewed by a physician to protect clinical intent and reduce avoidable rework during ethics/IRB review.
-
GCP-Aware Quality Control:
Structured QA checklist supports consistency, completeness, and terminology alignment appropriate for clinical trial documentation.
-
Native Russian + Uzbek Linguists:
Native linguists with English-source ICF focus.
-
Glossary and Terminology Consistency:
Master glossary ensures consistent medical language across all ICF sections and versions — enforced from initial ICF through every amendment.
-
Documentation Partner, Not a CRO:
We do not perform site selection, site qualification, investigator/PI assessment, patient recruitment, monitoring, or trial management. Those remain the CRO's role — we work alongside them.
Why Central Asia for Clinical Trials?
Central Asia represents a rapidly growing frontier for clinical trials. Uzbekistan has a population exceeding 36 million and one of the fastest-growing and largest pharmaceutical markets in Central Asia with a rapidly modernizing clinical-research regulatory environment. The region offers large treatment-naive patient populations, minimal trial competition, and cost-effectiveness.
On-the-Ground Familiarity
We work on the ground in Uzbekistan, with direct familiarity with the regional clinical environment and patient context — informing protocol and ICF realism, all under physician-led review. (Not site selection or investigator assessment.)
Ground-Verification Layer (Tiers 1 & 2)
Desk-only feasibility misses what's happening on the ground. MedDocIQ adds an in-country verification layer: working on the ground in Uzbekistan, we check the protocol's key assumptions — regional standard of care, patient pathways, operational realities, and how patients will understand the ICF — against the local clinical environment and against official/published sources, not just what's on the page. Findings are reviewed and interpreted by our physician team and carried into the Protocol Feasibility Memo and the ICF. It is a protocol-and-documentation reality check — not site selection, site qualification, or investigator assessment.
Our Process
MedDocIQ follows a structured, physician-led methodology: (1) Protocol Feasibility Review through an Uzbekistan-specific lens, (2) ICF Cultural Localization by native RU/UZ linguists, (3) Physician Clinical Validation for intent and terminology, (4) Audit-friendly delivery with full artifact package. For ongoing trials, we maintain terminology governance across all amendments and safety updates using the established Study Glossary and Term Decision Register.
About MedDocIQ
MedDocIQ is a US-based, physician-led clinical trial documentation partner — not a CRO. We localize and clinically validate patient-facing and regulatory documents and review protocols for documentation- and ICF-relevant execution risks for clinical trials in Uzbekistan and Central Asia. We do not perform site selection, site qualification, investigator/PI assessment, patient recruitment, monitoring, or trial management. Those remain the CRO's role — we work alongside them. The team combines physician clinical review, GCP-aware quality control, and native Russian and Uzbek linguists to deliver documentation that preserves clinical intent from first ICF through final close-out.
Coming Soon
Central Asia Expansion: Kazakhstan, Kyrgyzstan, and Tajikistan. Additional patient-facing document localization including recruitment materials, patient brochures, and participant diaries/questionnaires.
Navigate
Contact
Email:
contact@meddociq.com
LinkedIn:
linkedin.com/company/meddociq